 7. Patients with clinically significant cardiovascular disease: History of ischemic or hemorrhagic stroke within past 6 months; Uncontrolled hypertension, on at least 2 repeated determinations on separate days within past 3 months; Myocardial infarction or unstable angina within past 6 months; New York Heart Association grade III or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris within past 6 months; Clinically significant peripheral vascular disease within past 6 months; Pulmonary embolism, deep vein thrombosis DVT, or other thromboembolic event within past 6 months; Diagnosed congenital long QT syndrome; Any history of clinically significant ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes; Prolonged QTc interval on pre-entry electrocardiogram 450 msec; Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration. 